Literature DB >> 3045820

Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.

S Seelmeier1, H Schmidt, V Turk, K von der Helm.   

Abstract

The protease encoded by the human immunodeficiency virus (HIV) processes the viral gag and gag-pol protein precursor by posttranslational cleavage. In this study we have demonstrated by site-specific mutagenesis (Asp----Thr) and by pepstatin A inhibition that the recombinant HIV protease is an aspartic-type protease. Furthermore, incubation of HIV-infected H9 cells with pepstatin A inhibited part of the intracellular processing of the HIV gag protein yet had no apparent toxicity on HIV-infected cells during 48 hr of incubation.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3045820      PMCID： PMC282027          DOI： 10.1073/pnas.85.18.6612

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  33 in total

1.  Biochemical properties of p15-associated protease in an avian RNA tumor virus.

Authors:  K J Dittmar; K Moelling
Journal:  J Virol       Date:  1978-10       Impact factor: 5.103

2.  Effect of protease inhibitors on focus formation by murine sarcoma virus.

Authors:  Y Yuasa; H Shimojo; T Aoyagi; H Umezawa
Journal:  J Natl Cancer Inst       Date:  1975-05       Impact factor: 13.506

3.  Cleavage of Rous sarcoma viral polypeptide precursor into internal structural proteins in vitro involves viral protein p15.

Authors:  K von der Helm
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

4.  Pepstatin, a new pepsin inhibitor produced by Actinomycetes.

Authors:  H Umezawa; T Aoyagi; H Morishima; M Matsuzaki; M Hamada
Journal:  J Antibiot (Tokyo)       Date:  1970-05       Impact factor: 2.649

5.  Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor.

Authors:  C Debouck; J G Gorniak; J E Strickler; T D Meek; B W Metcalf; M Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

6.  A structural model for the retroviral proteases.

Authors:  L H Pearl; W R Taylor
Journal:  Nature       Date:  1987 Sep 24-30       Impact factor: 49.962

7.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

8.  Pepstatin, an inhibitor of leukokinin formation and ascitic fluid accumulation.

Authors:  L M Greenbaum; P Grebow; M Johnston; A Prakash; G Semente
Journal:  Cancer Res       Date:  1975-03       Impact factor: 12.701

9.  Properties of a P70 proteolytic factor of murine leukemia viruses.

Authors:  Y Yoshinaka; R B Luftig
Journal:  Cell       Date:  1977-11       Impact factor: 41.582

10.  Biochemical and immunological analysis of human immunodeficiency virus gag gene products p17 and p24.

Authors:  F D Veronese; T D Copeland; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103
View more
  48 in total

1.  Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease.

Authors:  H Jacobsen; L Ahlborn-Laake; R Gugel; J Mous
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor.

Authors:  A L Swain; M M Miller; J Green; D H Rich; J Schneider; S B Kent; A Wlodawer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

3.  Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.

Authors:  Mi Li; Alla Gustchina; Krisztina Matúz; Jozsef Tözsér; Sirilak Namwong; Nathan E Goldfarb; Ben M Dunn; Alexander Wlodawer
Journal:  FEBS J       Date:  2011-10-10       Impact factor: 5.542

4.  Identification of broad-based HIV-1 protease inhibitors from combinatorial libraries.

Authors:  Max W Chang; Michael J Giffin; Rolf Muller; Jeremiah Savage; Ying C Lin; Sukwon Hong; Wei Jin; Landon R Whitby; John H Elder; Dale L Boger; Bruce E Torbett
Journal:  Biochem J       Date:  2010-08-01       Impact factor: 3.857

Review 5.  Targeting structural flexibility in HIV-1 protease inhibitor binding.

Authors:  Viktor Hornak; Carlos Simmerling
Journal:  Drug Discov Today       Date:  2006-12-20       Impact factor: 7.851

6.  Atomistic simulations of the HIV-1 protease folding inhibition.

Authors:  Gennady Verkhivker; Guido Tiana; Carlo Camilloni; Davide Provasi; Ricardo A Broglia
Journal:  Biophys J       Date:  2008-03-28       Impact factor: 4.033

7.  Molecular dynamics studies on HIV-1 protease: a comparison of the flap motions between wild type protease and the M46I/G51D double mutant.

Authors:  Antonino Lauria; Mario Ippolito; Anna Maria Almerico
Journal:  J Mol Model       Date:  2007-09-06       Impact factor: 1.810

Review 8.  Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes.

Authors:  W G Dougherty; B L Semler
Journal:  Microbiol Rev       Date:  1993-12

9.  Mutational analysis of a native substrate of the human immunodeficiency virus type 1 proteinase.

Authors:  K Partin; H G Kräusslich; L Ehrlich; E Wimmer; C Carter
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

10.  Preparation and preliminary characterization of poly(ethylene glycol)-pepstatin conjugate.

Authors:  J Brygier; J Vincentelli; M Nijs; C Guermant; C Paul; D Baeyens-Volant; Y Looze
Journal:  Appl Biochem Biotechnol       Date:  1994-04       Impact factor: 2.926
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.